NICE: no evidence to approve Merck Serono's Erbitux, Roche's Avastin and Amgen's Vectibix for second-line mCRC
This article was originally published in Scrip
Executive Summary
Merck Serono's Erbitux (cetuximab), Roche's Avastin (bevacizumab) and Amgen's Vectibix (panitumumab) have failed to win recommendations from NICE, the health technology appraisal institute for England and Wales, for the treatment of metastatic colorectal cancer that has progressed after first-line chemotherapy.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.